Woodline Partners LP Aldeyra Therapeutics, Inc. Transaction History

Woodline Partners LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.43 - $4.85 $89,557 - $178,746	-36,855 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.25 - $5.17 $2.4 Million - $3.82 Million	-739,379 Reduced 95.25%	36,855 $164,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $9.63 $4.64 Million - $12.8 Million	-1,326,733 Reduced 63.09%	776,234 $3.11 Million
Q3 2021 Nov 15, 2021	BUY	$7.94 - $11.31 $3.13 Million - $4.46 Million	394,044 Added 23.06%	2,102,967 $18.5 Million
Q2 2021 Aug 16, 2021	BUY	$10.44 - $14.85 $10.2 Million - $14.5 Million	978,529 Added 133.97%	1,708,923 $19.4 Million
Q1 2021 May 17, 2021	BUY	$6.53 - $14.42 $4.77 Million - $10.5 Million	730,394 New	730,394 $8.68 Million

116

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $249M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.